1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
H. Lundbeck A/S

H. Lundbeck A/S

HLUBF
H. Lundbeck A/SUS flagOther OTC
5.94
USD
+0.22
- -
6.31BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
77.79
68.63
74.28
79.29
87.52
89.97
87.36
88.92
16.41
18.38
20.07
22.19
24.83
25.69
Basic EPS, GAAP
4.36
-0.78
-28.98
6.14
13.29
19.67
11.64
7.96
1.33
1.93
2.31
3.17
3.22
3.72
Free Cash Flow per Basic Share
11.45
0.31
-14.04
14.12
16.81
26.56
10.9
16.9
1.67
2.72
3.61
2.78
4.9
5.48
Dividend per Share
2
2.77
- -
- -
2.45
8
12
4.1
0.5
0.4
0.58
0.7
0.95
1.15
Book Value per Share
69.72
65.63
37.07
44.42
56.53
67.97
80.4
84.26
17.69
19.32
21.04
23.53
25.81
26.25
Tangible Book Value per Share
22.45
4.36
-5.14
4.34
23.37
31.35
-47.68
-29.01
-4.5
-1.73
1.36
-16.16
-10.96
-10.57
Basic Weighted Avg Shares
196
196
196
197
198
199
199
199
993
993
992
991
992
993
Sales/Revenue/Turnover
15,258
13,468
14,594
15,634
17,286
17,875
17,358
17,672
16,299
18,246
19,912
22,004
24,630
25,520
Operating Margin (%)
10.48
0.74
-46.7
14.66
25.8
28.3
20.02
11.26
12.33
15.63
16.05
14.86
21.42
22.46
Depreciation Expense
- -
1,453
7,026
1,554
- -
- -
1,670
2,793
1,710
1,811
2,012
1,876
1,865
- -
Net Income, GAAP
855
-153
-5,694
1,211
2,624
3,907
2,313
1,581
1,318
1,916
2,290
3,143
3,192
3,698
Effective Tax Rate (%)
41.92
- -
- -
43.86
38.65
26.13
23.56
17.05
16.64
22.55
23.49
15.49
28.86
28
Profit Margin (%)
5.6
-1.14
-39.02
7.75
15.18
21.86
13.33
8.95
8.09
10.5
11.5
14.28
12.96
14.49
Working Capital
4,845
2,184
-88
-252
2,365
4,073
-1,242
93
-206
3,213
5,299
4,430
3,930
3,656
LT Debt
2,141
3,259
3,687
1,708
57
- -
7,499
5,813
5,236
5,491
4,065
16,611
11,580
10,854
Total Equity
13,481
13,526
8,785
9,694
12,181
14,251
16,782
16,973
18,279
20,779
22,045
25,010
24,903
25,626
Return on Invested Capital (%)
6.04
- -
- -
10.6
22.82
28.14
12.9
6.3
6.76
8.67
9.12
8.04
9.48
10.75
Return on Capital (%)
6.59
- -
- -
12.74
25.75
31.6
12.09
6.9
6.08
8.38
9.36
9.96
9.21
9.77
Return on Common Equity (%)
6.37
-1.15
-56.48
15.1
26.34
31.68
15.69
9.66
7.68
10.43
11.43
14.22
13.04
14.91

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
76
74
74
LT Borrowings
11,924
11,185
10,446
LT Finance Leases
408
395
408
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
992
992
992
Market Capitalization
34,649
33,867
31,051

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13,359
12,783
12,647
Cash, Cash Equivalents & STI
3,479
3,433
1,956
Accounts Receivable, Net
5,609
3,605
6,092
Inventories
4,271
4,473
4,599
Total Current Liabilities
9,104
8,853
8,991
Payables & Accruals
- -
- -
- -
ST Debt
76
74
74
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.24%
8.1%
-0.43%
Free Cash Flow
-2.87%
19.58%
76.13%
Net Income, GAAP
5.89%
17.41%
1.56%
Sales/Revenue/Turnover
5.58%
7.15%
11.93%
Total Cash Common Dividend
- -
8.46%
35.88%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,288
5,453
5,722
5,541
22,004
2025
6,235
6,023
6,279
6,093
24,630
2026
7,125
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.01
0.78
0.78
- -
3.17
2025
1.13
0.97
1.11
- -
3.22
2026
1.67
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
0.7
2025
0.95
- -
- -
- -
0.95
2026
1.15
- -
- -
- -
- -

Company Description

APIChat
CEO
Charl van Zyl
Full Time Employees
5,707
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Ottiliavej 9 Valby Denmark 2500
IPO Date
Jul 13, 2022
Website
lundbeck.com
Similar Companies
Labomar S.p.A. (LBM.MI)
Seach Medical Group Ltd (SEMG.TA)
Evotec SE (EVO)
Juva Life Inc. (JUVA.CN)
Rapid Nutrition PLC (ALRPD.PA)
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK)
Business
H. Lundbeck A/S is a Denmark-based international pharmaceutical company specializing in the research, development, manufacturing, marketing, and sale of innovative therapies for brain diseases, including psychiatric and neurological disorders such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, migraine, and alcohol dependence. Founded in 1915 and headquartered in Valby, Copenhagen, the company operates in more than 50 countries with production facilities in Denmark, France, and Italy, and research centers in Denmark and the United States; its products are registered in over 80 countries worldwide. Lundbeck's core portfolio encompasses strategic brands including Rexulti/Rxulti (brexpiprazole) for depression, anxiety, and psychosis; Brintellix/Trintellix (vortioxetine) for depression; Abilify Maintena (aripiprazole) for psychosis; Vyepti (eptinezumab) for migraine prevention; Cipralex/Lexapro (escitalopram) and Cipramil (citalopram) for depression and anxiety; Ebixa (memantine) for Alzheimer's disease; Azilect (rasagiline) for Parkinson's disease; Northera (droxidopa) for neurogenic orthostatic hypotension; Sabril (vigabatrin), Onfi/Frisium (clobazam) for epilepsy; Selincro (nalmefene) for alcohol dependence; and mature antipsychotics such as Serdolect (sertindole), Clopixol/Cisordinol (zuclopenthixol), Fluanxol (flupentixol), and Truxal (chlorprothixene).[image:1 from products page] In recent developments, Lundbeck acquired Longboard Pharmaceuticals in 2024 for approximately $2.5 billion to add bexicaserin, a 5-HT2C agonist in development for developmental and epileptic encephalopathies including Dravet and Lennox-Gastaut syndromes; partnered with Iambic Therapeutics in 2024 to leverage AI-driven drug discovery for neurological diseases; and in September 2025 announced partnerships with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals to transition sales, marketing, access, and distribution in 27 markets across Europe and International Operations by December 2025, sharpening commercial focus on neuro-rare and neuro-specialty franchises while incurring one-off costs of DKK 390 million.